Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of SGLT2 inhibition on renal hemodynamics in type 2 diabetes and chronic kidney disease
2019-004447-80Phase 2Completed
- Sponsor
- University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Renal Blood Flow. Started Apr 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2019-004447-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004447-80.